RECRUITING

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.

Official Title

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Quick Facts

Study Start:2025-08-18
Study Completion:2026-08-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07095114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
  2. * Participants must be 18 years of age or older
  3. * Participant must be able to understand a written informed consent document and be willing to sign it
  4. * Participant must be assigned female at birth
  5. * Participant must have a Karnofsky performance score of greater than or equal to 70%
  6. * Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:
  7. * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
  8. * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
  9. * Agree to practice true abstinence from sexual intercourse
  10. * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
  11. * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
  12. * For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6
  1. * Participants who have received prior radiation treatment to the affected breast.
  2. * Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
  3. * Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
  4. * Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
  5. * Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Contacts and Locations

Study Contact

Michael Dominello, DO
CONTACT
3135769546
Mdominel@med.wayne.edu

Principal Investigator

Michael Dominello, DO
PRINCIPAL_INVESTIGATOR
Wayne State University

Study Locations (Sites)

Karmanos Cancer Institute
Detroit, Michigan, 48201
United States

Collaborators and Investigators

Sponsor: Barbara Ann Karmanos Cancer Institute

  • Michael Dominello, DO, PRINCIPAL_INVESTIGATOR, Wayne State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-18
Study Completion Date2026-08-08

Study Record Updates

Study Start Date2025-08-18
Study Completion Date2026-08-08

Terms related to this study

Additional Relevant MeSH Terms

  • Ductal Carcinoma in Situ
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer